Elaine Ullian - Vertex Pharmaceuticals Co-Lead Independent Director
| VRTX Stock | USD 399.92 5.64 1.43% |
Director
Ms. Elaine S. Ullian is CoLead Independent Director of Vertex Pharmaceuticals Incorporated. Ms. Ullian was a member of our Board of Directors since 1997. Ms. Ullian served as President and Chief Executive Officer of Boston Medical Center, a private, notforprofit, 626bed, academic medical center with a communitybased focus, from 1996 through January 2010. From 1994 to 1996, she served as President and Chief Executive Officer of Boston University Medical Center Hospital. From 1987 to 1994, Ms. Ullian served as President and Chief Executive Officer of Faulkner Hospital. She also serves as a director of Thermo Fisher Scientific Inc. and Hologic, Inc since 2011.
| Age | 69 |
| Tenure | 13 years |
| Address | 50 Northern Avenue, Boston, MA, United States, 02210 |
| Phone | 617 341 6100 |
| Web | https://www.vrtx.com |
Vertex Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.1317 % which means that it generated a profit of $0.1317 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2299 %, meaning that it created $0.2299 on every $100 dollars invested by stockholders. Vertex Pharmaceuticals' management efficiency ratios could be used to measure how well Vertex Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.18 in 2024. Return On Capital Employed is likely to rise to 0.21 in 2024. At this time, Vertex Pharmaceuticals' Return On Assets are fairly stable compared to the past year.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Joseph Goldstein | Regeneron Pharmaceuticals | 77 | |
| Elaine Heron | Biomarin Pharmaceutical | 70 | |
| Simeon George | Crispr Therapeutics AG | 41 | |
| Elizabeth Anderson | Biomarin Pharmaceutical | N/A | |
| Doug Cole | Editas Medicine | 54 | |
| Ham Sukjaroenkraisri | Ginkgo Bioworks Holdings | N/A | |
| Bonnie Bassler | Regeneron Pharmaceuticals | 55 | |
| Bradley Bolzon | Crispr Therapeutics AG | 56 | |
| Robert Hines | Ginkgo Bioworks Holdings | N/A | |
| Jerome Zeldis | PTC Therapeutics | 68 | |
| Gil Price | Sarepta Therapeutics | 58 | |
| Akshay Vaishnaw | Editas Medicine | 55 | |
| Michael Grey | Biomarin Pharmaceutical | 65 | |
| Arthur Ryan | Regeneron Pharmaceuticals | 75 | |
| JeanFrancois Formela | Intellia Therapeutics | 61 | |
| Richard Barry | Sarepta Therapeutics | 59 | |
| Kathy Rouan | Viking Therapeutics | 56 | |
| Marc TessierLavigne | Regeneron Pharmaceuticals | 58 | |
| Cynthia Collins | Editas Medicine | 54 | |
| Marsha Fanucci | Alnylam Pharmaceuticals | 64 | |
| Michael Brown | Regeneron Pharmaceuticals | 77 | |
Management Performance
| Return On Equity | 0.23 | ||||
| Return On Asset | 0.13 |
Vertex Pharmaceuticals Leadership Team
Elected by the shareholders, the Vertex Pharmaceuticals' board of directors comprises two types of representatives: Vertex Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vertex. The board's role is to monitor Vertex Pharmaceuticals' management team and ensure that shareholders' interests are well served. Vertex Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vertex Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| William Young, Independent Director | ||
| Jonathan JD, Executive Officer | ||
| Reshma Kewalramani, Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer | ||
| Stephanie Franklin, Senior Officer | ||
| Michael Parini, Executive Vice President and Chief Legal Officer | ||
| Alan Garber, Independent Director | ||
| Joshua Boger, Executive Director and Chairman of Science and Technology Committee | ||
| Mike Tirozzi, SVP Officer | ||
| Damian Esq, Chief VP | ||
| Jeffrey MD, Executive Chairman | ||
| Nina Devlin, Senior Officer | ||
| MD FASN, President CEO | ||
| Stuart BSc, Executive COO | ||
| John Gray, Senior Vice President Genetic Therapies | ||
| Margaret McGlynn, Independent Director | ||
| Sangeeta Bhatia, Director | ||
| Kristen CPA, Senior Officer | ||
| Terrence Kearney, Independent Director | ||
| Ian Smith, CFO, Executive Vice President | ||
| Kristen Ambrose, Tax, Accounting | ||
| Paul Silva, Senior Vice President Corporate Controller | ||
| David Altshuler, Independent Director | ||
| Jeffrey Chodakewitz, Chief Medical Officer and Senior Vice President - Global Medicines Development | ||
| Elaine Ullian, Co-Lead Independent Director | ||
| Amit Sachdev, Senior Vice President - Global Government Strategy, Market Access and Value | ||
| David Greenway, Director | ||
| Charles Wagner, CFO, Executive Vice President | ||
| Ourania Tatsis, Ex Officer | ||
| Amit JD, Executive Officer | ||
| Bruce Sachs, Co-Lead Independent Director | ||
| Susie Lisa, Senior Relations | ||
| Lloyd Carney, Independent Director | ||
| Michael Partridge, Vice President - Investor Relations | ||
| Yuchun Lee, Independent Director | ||
| Kimberly White, Senior Vice President and Chief Communications Officer | ||
| Stuart Arbuckle, Chief Commercial Officer and Executive VP | ||
| Thomas Graney, CFO, Senior Vice President | ||
| Charles Milstein, Executive Vice President Chief Legal and Administrative Officer | ||
| Jeffrey Leiden, Chairman of the Board and Presidentident, CEO |
Vertex Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vertex Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.23 | ||||
| Return On Asset | 0.13 | ||||
| Profit Margin | 0.37 % | ||||
| Operating Margin | 0.38 % | ||||
| Current Valuation | 91.44 B | ||||
| Shares Outstanding | 258.46 M | ||||
| Shares Owned By Insiders | 0.11 % | ||||
| Shares Owned By Institutions | 97.28 % | ||||
| Number Of Shares Shorted | 3.98 M | ||||
| Price To Earning | 24.57 X |
Vertex Pharmaceuticals Investors Sentiment
The influence of Vertex Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Vertex. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Vertex Pharmaceuticals' public news can be used to forecast risks associated with an investment in Vertex. The trend in average sentiment can be used to explain how an investor holding Vertex can time the market purely based on public headlines and social activities around Vertex Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Vertex Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Vertex Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Vertex Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Vertex Pharmaceuticals.
Vertex Pharmaceuticals Implied Volatility | 25.91 |
Vertex Pharmaceuticals' implied volatility exposes the market's sentiment of Vertex Pharmaceuticals stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Vertex Pharmaceuticals' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Vertex Pharmaceuticals stock will not fluctuate a lot when Vertex Pharmaceuticals' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Vertex Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Vertex Pharmaceuticals' short interest history, or implied volatility extrapolated from Vertex Pharmaceuticals options trading.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Vertex Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vertex Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vertex Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vertex Pharmaceuticals Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vertex Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Vertex Stock analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |
Is Vertex Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vertex Pharmaceuticals. If investors know Vertex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vertex Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.181 | Earnings Share 13.89 | Revenue Per Share 38.297 | Quarterly Revenue Growth 0.093 | Return On Assets 0.1317 |
The market value of Vertex Pharmaceuticals is measured differently than its book value, which is the value of Vertex that is recorded on the company's balance sheet. Investors also form their own opinion of Vertex Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Vertex Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vertex Pharmaceuticals' market value can be influenced by many factors that don't directly affect Vertex Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vertex Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vertex Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vertex Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.